Home › Opioid Overdose › NCT05683184

OMAR Opioid Use Disorder

Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Able to provide informed consent
* Male and female 18 years and older
* DSM-5 diagnosis of opioid use disorder (for OUD group)
* Physically healthy i.e., no clinically unstable medical conditions
* Written informed consent and have capacity to consent and comply with study procedures

Exclusion Criteria:

* Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).
* Presence of ferromagnetic metal in the body or heart pacemaker
* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits
* Are claustrophobic
* Hematocrit values lower than 30

About the study

The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.

What is being tested

• [11C]OMAR (drug)

Sponsor: Yale University · Participants: 30 · Started: Mar 10, 2023

Contact the study team

• Anahita Bassir Nia, MD · Phone: 203-974-7540
• Abby Dewey · Phone: 475-441-4190

Official record on ClinicalTrials.gov — NCT05683184

Locations in the U.S.

Conditions

• Opioid Overdose

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.